论文部分内容阅读
为建立以腺病毒为载体的GM－CSF基因转染瘤苗，并研究其体内抗肿瘤作用，应用携带有人GM－CSF基因的重组腺病毒（R－Ad5）载体转染BALB／c小鼠肝癌细胞株（H22），体外应用酶联免疫吸附试验（ELISA法）．检测GM－CSF表达水平，以GM—CSF基因转染的H22细胞进行致癌性研究。结果：（1）重组腺病毒载体能成功地介导GM－CSF基因转染H22细胞并能持续有效表达26～31天，瘤苗的辐照处理并不明显影响GM－CSF表达水平。（2）GM－CSF基因转染瘤苗体内致癌性显著降低。该结果揭示了应用GM－CSF基因转来瘤苗进行肿瘤基因治疗的可行性，为进一步研究肿瘤的GM－CSF基因治疗提供了依据．
In order to establish an adenovirus-borne GM-CSF gene transfected tumor vaccine and study its anti-tumor effect in vivo, the recombinant adenovirus (R-Ad5) vector carrying the human GM-CSF gene was used to transfect BALB/c mouse liver cancer. Cell line (H22), in vitro application of enzyme-linked immunosorbent assay (ELISA). The expression level of GM-CSF was measured and H22 cells transfected with GM-CSF gene were used for carcinogenicity study. Results: (1) The recombinant adenovirus vector successfully transfected GM-CSF gene into H22 cells and could continue to express effectively for 26 to 31 days. Irradiation treatment of tumor vaccine did not significantly affect the expression level of GM-CSF. (2) The carcinogenicity of GM-CSF gene transfected tumors was significantly reduced. The results revealed the feasibility of using GM-CSF gene transfer tumor vaccine gene therapy to provide a basis for further study of tumor GM-CSF gene therapy.